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adult serotonin receptors 
Abstract 
Background: Antipsychotic drug (APD) prescription/use in children has increased significantly worldwide, 
despite limited insight into potential long-term effects of treatment on adult brain functioning. While initial 
long-term studies have uncovered alterations to behaviors following early APD treatment, further 
investigations into potential changes to receptor density levels of related neurotransmitter (NT) systems 
are required. Methods: The current investigation utilized an animal model for early APD treatment with 
aripiprazole, olanzapine, and risperidone in male and female juvenile rats to investigate potential long-
term changes to the adult serotonin (5-HT) NT system. Levels of 5-HT1A, 5-HT2A, and 5-HT2C receptors 
were measured in the prefrontal cortex (PFC), caudate putamen (CPu), nucleus accumbens (NAc), and 
hippocampus via Western Blot and receptor autoradiography. Results: In the male cohort, long-term 
changes to 5-HT2A and 5-HT2C receptors were found mostly across hippocampal and cortical brain 
regions following early aripiprazole and olanzapine treatment, while early risperidone treatment changed 
5-HT1A receptor levels in the NAc and PFC. Lesser effects were uncovered in the female cohort with 
aripiprazole, olanzapine and risperidone to alter 5-HT1A and 5-HT2A receptors in NAc and hippocampal 
brain regions, respectively. Conclusion: The results of this study suggest that early treatment of various 
APDs in juvenile rats may cause gender and brain regional specific changes in 5-HT2A and 5-HT2C 
receptors in the adult brain. 
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Background: Antipsychotic drug (APD) prescription/use in children has increased significantly 
worldwide, despite limited insight into potential long-term effects of treatment on adult brain 
functioning. While initial long-term studies have uncovered alterations to behaviors following 
early APD treatment, further investigations into potential changes to receptor density levels of 
related neurotransmitter (NT) systems are required.
Methods: The current investigation utilized an animal model for early APD treatment with 
aripiprazole, olanzapine, and risperidone in male and female juvenile rats to investigate potential 







 receptors were measured in the prefrontal cortex (PFC), caudate putamen (CPu), nucleus 
accumbens (NAc), and hippocampus via Western Blot and receptor autoradiography.




 receptors were found 
mostly across hippocampal and cortical brain regions following early aripiprazole and olan-
zapine treatment, while early risperidone treatment changed 5-HT
1A
 receptor levels in the NAc 
and PFC. Lesser effects were uncovered in the female cohort with aripiprazole, olanzapine 




 receptors in NAc and hippocampal brain regions, 
respectively.
Conclusion: The results of this study suggest that early treatment of various APDs in juvenile 




 receptors in 
the adult brain.
Keywords: antipsychotic drug, serotonin, risperidone, olanzapine, aripiprazole, development, 
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Introduction
Antipsychotic drug (APD) prescription and use is rapidly increasing globally, 
despite a lack of knowledge on the safety and efficacy of APD use on the developing 
brain.1–10 Second-generation APDs including aripiprazole, olanzapine, and risperidone 
are currently commonly being prescribed (mostly off-label) for the treatment of a 
variety of childhood disorders from mental illnesses, including depression and child-
onset schizophrenia,5,11,12 to various behavioral disorders, including autism spectrum 
disorder.13–15
While APDs are known to elicit their therapeutic effects predominantly through a 
strong affinity and subsequent antagonistic mechanism of action on both the dopamine 
(DA) D
2




 receptors,16–22 both the dopamin-
ergic and serotonergic neurotransmitter (NT) systems have been proven to undergo, 
and be heavily involved in, numerous critical neurodevelopmental processes during 
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De santis et al
the childhood/adolescent period.19,23–29 Specifically, 5-HT is 
known to play an early significant and concentration-dependent 
trophic role in neural development and neurite growth8,26,30–33 
and then also undergo specific phases of development as a NT 
system (eg, synaptogenesis and regressive elimination).8,31
Subsequently, there is the potential that early insult/use of 
potent APDs at this critical time of neurodevelopment may 
have the ability to cause long-term alterations to the function-
ality of the NT systems, including that of 5-HT, in a manner 
that precedes normal brain functioning.8,27,34,35 With altera-
tions to the 5-HT NT system previously linked to changes 
in both behavioral attributes (including locomotor, anxiety, 
and depressive-like behaviors) and furthermore negatively 
correlated to dopamine NT functioning,36–38 prescription 
and use of APDs during the critical neurodevelopmental 
time period have the potential to lead to long-term deficits 
in brain functioning.10,35,39
Although current clinical investigations have found some 
benefits to childhood/adolescent APD use in the treatment of 
the symptomology of various mental illnesses over a short-
term time period (1–2 months) and a time period of up to 
6 months,40–42 the potential for the use of potent APDs to cause 
long-term alterations to adult brain functioning, especially in 
a clinical setting, is still mostly unknown.19,43,44
Previously completed animal studies investigating the 
effects of juvenile APD use on the developing brain, includ-
ing previous studies completed in our laboratory, have found 
that early treatment of up to 4 weeks can result in various 
significant long-term changes to behavioral attributes39 and 
immediate alterations to NT pathways including the 5-HT 
NT system.45,46 While investigations into the distribution/







 receptors, have found various immediate 
alterations following short-term APD treatment,44,45,47 studies 
investigating the long-term effects of early APD treatment 
have been found to be limited to the DA NT system.19,35,48
The present study was subsequently conducted in order 
to investigate the long-term effects of juvenile APD use 
with aripiprazole, olanzapine, and risperidone on the adult 
5-HT NT system in both male and female rats. Specifically, 







 receptors were investigated in cortical, striatal, and 




Timed pregnant Sprague Dawley rats were obtained at gesta-
tion day 16 from the Animal Resource Centre (Perth, WA, 
Australia) and housed in individual cages under environmen-
tally controlled conditions (22°C, light cycle from 7 am to 
7 pm and dark cycle from 7 pm to 7 am). Each was allowed 
ad libitum access to standard laboratory chow diet (3.9 kcal/g: 
10% fat, 74% carbohydrate, and 16% protein) and water. The 
day of birth was considered postnatal day (PD) 0. Pups were 
sexed on PD14, and then, 96 rats (48 males and 48 females) 
were weaned on PD20. Rats were housed in individual rat 
cages with top wire lids, in which they were able to smell 
and see each other through the lids.
Drug treatment groups
After weaning and prior to the commencement of drug treat-
ment, all animals were trained for self-administration by 
feeding them cookie dough (0.3 g) without drugs two times 
per day for PD18–21. Rats were then randomly assigned to 
one of the four experimental groups per gender on PD21 
(n=12/group): 1) aripiprazole (Otsuka, Tokyo, Japan), 2) 
olanzapine (Eli Lilly, Indianapolis, IN, USA), 3) risperidone 
(Apotex, Toronto, ON, Canada), and 4) control (vehicle). 
Drug treatment was carried out in juvenile rats from PD22–50, 
a time period equivalent to the childhood/adolescent phase in 
humans.26 In order to replicate a clinical setting, a staggered 
drug treatment pattern was used, where lower APD dosages 
are slowly increased to a final dosage amount.49 Specifi-
cally, APD doses were initiated on PD22 at 0.2 mg/kg for 
aripiprazole, 0.25 mg/kg three times per day for olanzapine, 
and 0.05 mg/kg three times per day for risperidone and were 
increased in three steps over the first 7 days of the 4-week 
treatment period to achieve a final dose on PD28 of 1 mg/kg 
three times per day for aripiprazole, 1 mg/kg three times per 
day for olanzapine, and 0.3 mg/kg three times per day for ris-
peridone. Drug treatment was administered orally to each drug 
treatment group via mixing cookie dough powder (containing 
cornstarch 37%, sucrose 37%, gelatine 17%, and casein 9%) 
with a small amount of distilled water until even in consis-
tency. All animals were individually observed for the duration 
of each treatment to ensure that they completely consumed the 
cookie dough pellet and thus received a full dosage. Animals 
in the control group also received an equivalent pellet without 
the drug. In consideration of a shorter half-life of APDs in 
rats, and to ensure a consistently high drug concentration in 
replication of the clinical scenario of oral administration once 
per day,50 APDs were administered three times per day (at 7, 2, 
and 10 h) with 8±1 hour intervals. The proposed dosages are 
translated from a clinical setting and within the recommended 
dosage ranges for the psychiatric treatment of pediatric 
patients. Dosage calculations are based on the body surface 
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Juvenile aPD affects 5-hT receptors in adult rats
rats in the US Food and Drug Administration guideline for 
clinical trials.42,49,51,52 The relevant human equivalent dose 
(HED) is therefore calculated by the following formula: ani-
mal dose (mg/kg) × animal Km (6)/human child Km (25) × 
body weight (Km factor, body weight (kg) divided by body 
surface area (m2), is used to convert the mg/kg dose to a mg/
m2 dose). Therefore, for an adolescent with an average weight 
of 40 kg, the utilized dosages for aripiprazole (1 mg/kg in rats) 
and olanzapine (1 mg/kg in rats) equals to a clinical dosage 
of 9.6 mg, while risperidone (0.3 mg/kg) equals to a clinical 
dosage of 2.88 mg, all within a clinically relevant range for 
adolescent patients. Previous reports have demonstrated that 
at this dosage amount, aripiprazole drug treatment reaches 
.90% DA D
2
 receptor occupancy rates in the rat brain,53 while 
olanzapine and risperidone reach 65%–80% DA D
2
 receptor 
occupancy rates.54,55 These dosage amounts have also been 
shown to be physiologically and behaviorally effective in our 
laboratory, with similar dosages seen to induce weight gain 
and changes in hypothalamic neuropeptide Y expression in 
adolescent rats,56 while immediate alterations to both DA 
receptor and 5-HT receptor binding have been reported in 
juvenile rats.45 All experimental procedures were approved 
by the Animal Ethics Committee, University of Wollongong, 
Wollongong, NSW, Australia (AE 12/20) and complied with 
Australian Code of Practice for the Care and Use of Animals 
for Scientific Purpose (2004).
histological procedures
After a maturation period where all animals were monitored 
regularly and allowed to mature (PD51–105), all rats were sac-
rificed on PD106 via carbon dioxide asphyxiation. Euthanasia 
was completed between 9 am and 11.30 am to minimize the 
potential circadian-induced variation of protein expression. 
Brain tissue was removed immediately following euthanasia, 
frozen in liquid nitrogen, and stored at −80°C until analysis. 
Six brains from each drug treatment group (n=12) were then 
randomly assigned for Western Blot analyses, and the remain-
ing six brains from each treatment group were then used for 
receptor autoradiography experiments. Brain regions involved 
in both serotonergic signaling and the therapeutic actions of 
APDs, including the prefrontal cortex (PFC), caudate putamen 
(CPu), nucleus accumbens (NAc), and hippocampus, were 
dissected in order to detect 5-HT receptor levels.
Microdissection (Western Blot analyses)
Tissue from aforementioned brain regions to be used for 
Western Blot analysis was collected using microdissection 
puncture techniques, following a standard procedure in 
our laboratory.57–60 Briefly, 500 µm thick sections were cut 
at −14°C using a cryostat (Leica CM1850; Leica Microsys-
tems, Wetzler, Germany) and collected bilaterally using a 
microdissection puncher on glass slides.
receptor autoradiography
Tissue from brains selected for receptor autoradiography 
were collected via coronally dissected sections at −18°C into 
14 µm using a cryostat (Leica CM1850). Once dissected, sec-
tions were thaw-mounted onto poly-l-lysine (Sigma-Aldrich 
Co., St Louis, MO, USA)-coated glass slides and stored 
at −20°C. A set of sections from each animal were stained 
with the 0.5% cresyl violet solution (Nissl staining) and 
used to confirm the identification of anatomical structures.
Western Blot analyses
Tissues obtained from individual rats were homogenized in 
ice-cold homogenizing buffer (9.8 mL of NP-40 cell lysis 
buffer; Thermo Fisher Scientific, Waltham, MA, USA; 
100 µL of β-glycerophosphate; 50 mM; Thermo Fisher 
Scientific; 33.3 µL of phenylmethane sulfonyl fluoride; 
0.3 M; Sigma-Aldrich Co.; and 100 µL of Protease Inhibitor 
Cocktail; Sigma-Aldrich Co.). All samples were then cen-
trifuged, with the supernatant solution collected and stored 
at −80°C until required.
DC™ Protein Assays (#500-0114; Bio-Rad Laboratories 
Inc., Hercules, CA, USA) were completed at A
750 nm
 to spectro-
photometrically quantify total protein concentrations. A range 
of sample protein concentrations were pretested in each region 
(2, 2.5, 4, 5, 6, 7.5, 8, and 10 µg). A total of 10 µg of protein 
was selected for PFC, CPu, and NAc regions, while 8 µg 
of protein was selected for the hippocampus as it best fitted 
the linear range of signal detection for all tested antibodies. 
Homogenized brain samples containing the aforementioned 
microgram concentration of protein were then first heated at 
95°C in the loading buffer (950 µL of Laemmli buffer; Bio-Rad 
Laboratories Inc.; and 50 µL of β-mercaptoethanol; Sigma-
Aldrich Co.) for 5 minutes to denature the protein, then placed 
on ice, and centrifuged for 2 minutes at 4°C. The samples were 
then loaded into 4%–20% Criterion™ TGX™ Precast Gels 
(Bio-Rad Laboratories Inc.) and underwent electrophoresis 
in sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS PAGE) running buffer (100 mL of 10× SDS-PAGE run-
ning buffer; Bio-Rad Laboratories Inc.; and 900 mL of distilled 
water) at 140 V for 70 minutes. Proteins on the gels were then 
transferred electrophoretically using the Bio-Rad Midi Format 
1-D Electrophoresis Systems onto a polyvinylidene difluoride 
(PVDF) membrane (Bio-Rad Laboratories Inc.) in ice-cold 
transfer buffer (150 mL of 10× tris/glycine buffer; Bio-Rad 
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of distilled water) at 100 V for 1 hour. In order to detect the 
proteins of interest, PVDF membranes were incubated in 
tris-buffered saline–Tween (TBST) (Sigma-Aldrich Co.) solu-
tion containing 5% Blotting-Grade Blocker (nonfat dry milk 
powder) (Bio-Rad Laboratories Inc.) for 1 hour at room tem-
perature (RT). Membranes were then incubated overnight with 
the primary antibody, including 5-HT
1A
 (1:2,000; #ab85615; 
Abcam, Cambridge, UK), 5-HT
2A
 (1:1,000; #sc-50397; Santa 
Cruz Biotechnology Inc., Dallas, TX, USA), and 5-HT
2C
 
(1:1,000; #sc-15081; Santa Cruz Biotechnology Inc.), diluted 
in TBST buffer containing either 1% bovine serum albumin 
(BSA) (5-HT
1A





). Membranes were either washed three times with 




) and then incubated 
with horseradish peroxidase (HRP)-conjugated goat antirabbit 
secondary antibody for 1 hour at RT (5-HT
1A
 – 1:5,000 and 
5-HT
2A
 – 1:3,000; EMD Millipore, Billerica, MA, USA) or 
washed three times for 20 minutes (5-HT
2C
) and then incubated 
with HRP-conjugated donkey antigoat secondary antibody 
for 45 minutes at RT (5-HT
2C
 – 1:2,000; Abcam). Second-
ary antibodies were diluted in TBST buffer containing either 
1% BSA (5-HT
1A





). Three TBST washes then followed secondary 
antibody incubation, and proteins of interest were visualized 
using the Classico Western horseradish peroxidase (HRP) sub-
strates (EMD Millipore) and Amersham Hyperfilm ECL (GE 
Healthcare Life Sciences, Wauwatosa, WI, USA). Membranes 
were then re-probed with mouse antiactin polyclonal antibody 
(1:10,000, #MAB1501; EMD Millipore) and HRP-conjugated 
rabbit antimouse secondary antibody (1:3,000, #7076; Cell 
Signaling Technology, Danvers, MA, USA).
Immunoreactive signals were quantified using the GS-800 
image densitometry and Quantity One software (Bio-Rad 
Laboratories Inc.), and the values were corrected based 
on their corresponding actin levels. For 5-HT
1A
, the band 
at ~62 kDa was detected and quantified,61 while for 5-HT
2A
, 
the band at ~55 kDa was detected and quantified.62,63 Fur-
thermore, for 5-HT
2C
, a band at ~55 kDa was detected and 
quantified.64 The β-actin protein was quantified at 46 kDa. 
Western Blot gels were arranged by gender, in which each 
gel contained 24 samples (six rats/group × four treatments 
[ie, three APDs and one vehicle] × one gender). In order to 
control for variability, all samples were run in duplicate at 
second gels at the same sample arrangement and the values 
of each drug treatment group and control corrected based 
on their corresponding actin levels. Samples from male 
and female rats were run in different gels. All results were 
normalized by taking the value of the vehicle group of each 
gender as 100% to obtain a comparative value.
receptor autoradiography 
and quantification
Experimental procedures for 5-HT
2A
 binding autoradiography 





 binding autoradiography was also 
completed; however, binding results were too low and thus 
discounted from further analysis.
5-hT2a receptor binding procedures
Brain sections for 5-HT
2A
 receptor binding were thawed at 
RT and then preincubated in 170 mM tris buffer (pH 7.4) 
for 15 minutes. Slides with sections were then incubated for 
2 hours with 2 nM [3H]Ketanserin (specific activity: 47.3 Ci/
mmol; PerkinElmer Inc., Waltham, MA, USA) in 170 mM 
tris buffer at RT to determine total binding. Nonspecific 
binding was determined with the addition of 2 µM Spiperone 
(Sigma-Aldrich Co.) to subsequent sections. Following 
incubation, sections were washed four times for 2 minutes 
in ice-cold buffer, dipped in ice-cold distilled water, and 
then air dried.66,67
Quantification
Following the completion of receptor binding experiments, 
all slides were exposed to Amersham Hyperfilm ECL for 
2–3 months, along with autoradiographic standards ([3H]
microscales from Amersham), in X-ray film cassettes. Quan-
titative analysis of binding images was conducted following 
the relevant exposure time, using the Multi-Analyst image 
analysis system (Bio-Rad Laboratories Inc.), connected to a 
GS-800 Imaging Densitometer (Bio-Rad Laboratories Inc.). 
Optical density measurement was then converted into femto-
moles of [3H] ligand per milligram of tissue equivalent (TE) 
by comparing to the standard. Specific binding was calculated 
by subtracting nonspecific binding from total binding. A set 
of sections from each animal were stained with the 0.5% 
cresyl violet solution (Nissl staining), for the purpose of 
confirmation of anatomical structures. Specific brain regions 
in this project were identified by reference to the Nissl-stained 
sections, along with a standard rat brain atlas.68
statistical analysis
Statistical analysis of collected data was completed with 
the use of SPSS software (Windows Version 19.0; IBM 
Corporation, Armonk, NY, USA). Distribution of data 
was examined through the Kolmogorov–Smirnov test. All 
normally distributed data were also analyzed by two-way 
analysis of variance (ANOVA) (gender × treatment). Male 
and female data sets were then also analyzed separately by 
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Juvenile aPD affects 5-hT receptors in adult rats
multiple comparisons between the treatment groups. Data 
that were not distributed normally were analyzed via the non-
parametric Mann–Whitney U test. All data were analyzed per 
investigated brain region. The data were expressed as mean ± 
standard error of the mean (SEM). Statistical significance 
was accepted when P,0.05.
Results
long-term effects of adolescent aPD 
treatment on 5-hT1a receptor levels
A significant effect of treatment on 5-HT
1A
 receptor protein 





=3.791, P,0.02), while a significant effect 
of gender was also observed in the NAc (F
1,44
=13.584, 
P,0.01). Furthermore, a significant interaction between the 
two factors was found in the CPu (F
3,46
=2.860, P=0.050) and 
a trend toward a significant interaction was found in the NAc 
(F
3,44
=2.559, P=0.070). Post hoc analysis uncovered that 
early risperidone treatment decreased 5-HT
1A
 expression in 
the PFC (−23.8%, P,0.02) when compared with the con-
trol (Figures 1A′ and A″ and S1). In the male cohort, early 
APD treatment had a significant effect on the expression of 
5-HT
1A
 receptors in the NAc (F
3,22
=5.091, P,0.01) of adult 
rats. Further analysis revealed that early risperidone treatment 
trended to significantly decrease 5-HT
1A
 receptor expression 
in the NAc (−7.0%, P=0.081) (Figures 1 and S1). Analysis 
of the female cohort found trends toward significant effects 





=2.695, P=0.079). Post hoc analysis revealed 
that early aripiprazole treatment decreased 5-HT
1A
 receptor 
expression in the NAc (−16.6%, P=0.054) when compared 
with the control group. No significant alterations were uncov-
ered in the CPu (Figures 1B′ and B″ and S1) or hippocampus 
(Figures 1D′ and D″ and S1) of treated animals in comparison 
to the control, across either gender.
long-term effects of adolescent aPD 
treatment on 5-hT2a receptor levels
Two-way ANOVA tests (gender × treatment) revealed a sig-
nificant effect of treatment on 5-HT
2A
 receptor protein expres-
sion levels in the hippocampus (F
3,45
=4.913, P,0.01), while 
a significant effect of gender was found in the hippocampus 
(F
1,45
=17.745, P,0.001) and CPu (F
1,46
=4.541, P,0.05). 
Additionally, a significant interaction between the factors 





=3.972, P,0.02). Analysis of the male cohort 
via one-way ANOVA (treatment) uncovered a significant 
effect of early APD treatment on 5-HT
2A
 receptor expres-
sion in the NAc (F
3,22
=3.378, P,0.05), and hippocampus 
(F
3,22
=4.054, P,0.05). Furthermore, a trend to significant 
effect was also discovered in the PFC (F
3,22
=3.035, P=0.054). 
Post hoc analysis discovered that aripiprazole treatment 
was found to decrease 5-HT
2A
 receptor levels in the PFC 
(−78.0%, P=0.081) upon comparison to the control group. 
In the female cohort, one-way ANOVA found a significant 
effect of early APD treatment on 5-HT
2A
 expression in the 
PFC (F
3,22
=3.233, P,0.05) (Figures 2A′ and A″ and S2) 
and hippocampus (F
3,21
=4.738, P,0.02) (Figures 2D′ and 
D″ and S2). Further analysis via post hoc tests discovered 
decreases to 5-HT
2A
 receptor expression in the hippocampus 
following early olanzapine (−62.4%, P,0.01) treatment. No 
significant changes in the expression of 5-HT
2A
 receptors 
were uncovered in the CPu (Figures 2B′ and B″ and S2) or 
NAc (Figures 2C′ and C″ and S2) of APD animals in compari-
son to the control, across both male and female cohorts.
Examples of [3H]Ketanserin binding to 5-HT
2A
 are pre-
sented in Figure 3. Detected levels of 5-HT
2A
 in the CPu of 
females and males, however, were discounted, as expression 
was too low for accurate quantification. Analysis via two-way 
ANOVA (gender × treatment) found a significant effect of 
early APD treatment on the expression of 5-HT
2A
 receptors 
in the hippocampus (F
3,41
=2.106, P,0.01), along with a 
significant interaction between the two factors (F
3,41
=1.228, 
P,0.05). A trend to significant effect of treatment was also 
uncovered in the PFC of rats (F
3,43
=4.004, P=0.079). Post hoc 
analysis revealed that early treatment with both aripiprazole 
(−49.0%, P,0.02) and risperidone (−51.1%, P,0.01) sig-
nificantly decreased 5-HT
2A
 expression in the hippocampus 
in comparison to the control. When subsequently divided by 
gender, analysis of the male cohort demonstrated a significant 
effect of early APD treatment on 5-HT
2A
 receptor expres-
sion in the PFC (F
3,21
=4.010, P,0.05) and hippocampus 
(F
3,21
=6.274, P,0.01). Further analysis via post hoc revealed 
that early treatment with aripiprazole decreased 5-HT
2A
 
binding in the PFC (−44.3%, P=0.064) and hippocampus 
(−48.8%, P,0.05). Similar decreases were also observed fol-
lowing risperidone treatment in the PFC (−60.2%, P,0.02) 
and hippocampus (−69.5%, P,0.01) and olanzapine treat-
ment in the hippocampus (−44.7%, P=0.063). No significant 
effects were found in the female cohort between the APD 
treatment group and control.
long-term effects of adolescent aPD 
treatment on 5-hT2c receptor levels
Analysis of 5-HT
2C
 expression via two-way ANOVA 
(gender × treatment) uncovered a significant effect of treat-
ment on 5-HT
2C
 receptor protein expression in the PFC 
(F
3,44
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Figure 1 effects of three aPDs on 5-hT1a expression levels in the PFc (A′, A″), cPu (B′, B″), Nac (C′, C″), and hipp (D′, D″) of female and male rats.
Notes: sprague Dawley rats were treated chronically with aripiprazole (1.0 mg/kg, tid), olanzapine (1.0 mg/kg, tid), risperidone (0.3 mg/kg, tid), or control (vehicle). The 
number of samples per gender per group is 6. Data were expressed as mean ± seM. *P,0.05 vs control. The representative bands of Western Blot are shown.
Abbreviations: aPDs, antipsychotic drugs; cPu, caudate putamen; hipp, hippocampus; 5-hT, serotonin; Nac, nucleus accumbens; PFc, prefrontal cortex; seM, standard 
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Figure 2 effects of three aPDs on 5-hT2a expression levels in the PFc (A′, A″), cPu (B′, B″), Nac (C′, C″), and hipp (D′, D″) of female and male rats.
Notes: sprague-Dawley rats were treated chronically with aripiprazole (1.0 mg/kg, tid), olanzapine (1.0 mg/kg, tid), risperidone (0.3 mg/kg, tid), or control (vehicle). 
The number of samples per gender per group is 6. Data expressed as mean ± seM. **P,0.01 vs control. The representative bands of Western Blot are shown.
Abbreviations: aPDs, antipsychotic drugs; cPu, caudate putamen; hipp, hippocampus; Nac, nucleus accumbens; 5-hT, serotonin; PFc, prefrontal cortex; seM, standard 
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P,0.001) of rats. Additionally, a significant effect of gender 
was found in the hippocampus (F
1,45
=16.265, P,0.001), 
while a significant interaction between the factors was also 
found in the hippocampus (F
3,45
=7.511, P,0.001). Post hoc 
analysis uncovered that early treatment with both aripipra-
zole (−50.2%, P,0.05) and olanzapine (−42.5%, P=0.078) 
significantly decreased 5-HT
2C
 expression in the PFC in 
comparison to the control. Following analysis of the male 
cohort via one-way ANOVA, a significant effect of early 
APD treatment was discovered in the PFC (F
3,20
=8.004, 
P,0.01) and hippocampus (F
3,22
=15.474, P,0.001), 
while a trend to significant effect was found in the CPu 
(F
3,22
=2.946, P=0.059). Post hoc analysis found decreases 
in 5-HT
2C
 receptor expression in the PFC following early 
APD treatment with aripiprazole (−45.1%, P,0.05) and 
olanzapine (−50.1%, P,0.01) (Figures 4A′ and A″ and S3). 
Additionally, increases in 5-HT
2C
 receptor expression were 




Figure 3 examples of 5-hT2a receptor binding in the adult rat brain following childhood/adolescent aPD treatment.
Notes: The schematic diagram is adapted from Paxinos g, Watson c. The Rat Brain in Stereotaxic Coordinates. 6th edition. london: elsevier; 2007. © academic Press 2007.68 
showing the level of Bregma for each investigated region (A: PFc, 4.68 mm; B: cPu and Nac, 1.08 mm; C: hipp, −2.76 mm). (A′–C′) examples of autoradiograms to 
demonstrate [3h]Ketanserin binding to 5-hT2a receptors. The scale bar applies to all autoradiograms and is 2.0 mm for a′, 2.8 mm for B′, and 3.2 mm for c′.
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Figure 4 effects of three aPDs on 5-hT2c expression levels in the PFc (A′, A″), cPu (B′, B″), Nac (C′, C″), and hipp (D′, D″) of female and male rats.
Notes: sprague Dawley rats were treated chronically with aripiprazole (1.0 mg/kg, tid), olanzapine (1.0 mg/kg, tid), risperidone (0.3 mg/kg, tid), or control (vehicle). 
The number of samples per gender per group is 6. Data expressed as mean ± seM. *P,0.05, **P,0.01, ***P,0.001 vs control. The representative bands of Western Blot 
are shown.
Abbreviations: aPDs, antipsychotic drugs; cPu, caudate putamen; hipp, hippocampus; 5-hT, serotonin; Nac, nucleus accumbens; PFc, prefrontal cortex; seM, standard 
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with both aripiprazole (+41.5%, P,0.05) and risperidone 
(+79.6%, P,0.001) (Figures 4D′ and D″ and S3), while no 
alterations were uncovered in either the CPu (Figures 4B′ 
and B″ and S3) or the NAc (Figures 4C′ and C″ and S3). 
No significant alterations to 5-HT
2C
 receptor expression, 
however, were found in the female cohort.
Discussion
The present study has, for the first time, provided insight into 
the long-term effects of early (juvenile) treatment with the 
APDs aripiprazole, olanzapine, and risperidone on the density 
of 5-HT receptors in the adult brain. Our investigation has 
revealed that juvenile APD treatment during the critical neu-





 receptors, predominantly 
in hippocampal and cortical brain regions. Furthermore, we 
have uncovered more widespread alterations to the density 
of male 5-HT receptors in comparison to female 5-HT recep-




 receptors uncovered 
across multiple drug treatment groups.
While previous investigations into the long-term effects 







tors have, to our knowledge, not been completed, numerous 
studies have examined the immediate effects of aripiprazole, 
olanzapine, or risperidone treatment on the density of 5-HT 
receptors in young45,46,69 and adult65,67,70,71 rodents, over both 
short- and long-term treatment periods. Such investiga-
tions have uncovered a trend for APD treatment to result in 





subtypes following a cessation of treatment. We believe 
that our investigation is the first to identify that if treated in 
a juvenile animal, this alteration to 5-HT receptor density is 
still prominent in adulthood.
Long-term alterations to 5-HT
2A
 receptors after early APD 
exposure were uncovered in hippocampal and cortical brain 
regions in the current study. In the male cohort, significant 
decreases to the density of 5-HT
2A
 receptors were found in 
the hippocampus of adult brains following juvenile treatment 
with the APDs aripiprazole, olanzapine, and risperidone. 
Furthermore, similar decreases were also found in the PFC 
of those that underwent early treatment with aripiprazole 
and risperidone in comparison to the control. Decreases in 
5-HT
2A
 receptor densities were also found in the hippocampus 
of females following treatment with the APDs olanzapine 
and risperidone.
Although previous investigations into the immediate 
effects of short- and long-term treatments with olanzapine 
have also found region-specific alterations to the density 
levels of 5-HT
2A
 receptors of both young45,69 and adult67,70,71 
rats, results from the current study extended that of previ-
ous findings. Specifically, while decreases in 5-HT
2A
 levels 
have been observed in the hippocampus of the present study, 
previous investigations over multiple time periods, and 
across both genders, have found no changes to hippocampal 
5-HT
2A
 receptor levels in the adult brain following olanzapine 
treatment.70,71 Furthermore, while no changes in 5-HT
2A
 levels 
were uncovered in the PFC of our investigation, olanzapine 
has been found to immediately decrease PFC 5-HT
2A
 receptor 
levels in young rats following short-term treatment periods45,69 
and adult rats following both short-term70,71 and long-term 
treatment periods.67 While studies on the short- and long-term 
effects of risperidone treatment in both young and adult rats 
have also uncovered similar significant decreases in 5-HT
2A
 
receptor levels in the PFC,45,46,70 no changes in 5-HT
2A
 levels 
in brain regions including the CPu, NAc, and hippocampus 
have been previously uncovered.45,69,70 In addition, although 
significant decreases in 5-HT
2A
 receptors were observed 
in both the hippocampus and PFC of animals treated with 
aripiprazole in the present study, limited investigations have 
previously been completed investigating the potential for 
aripiprazole’s antagonistic actions on 5-HT
2A
 receptors to 
cause short- or long-term changes. While one investigation 
into the immediate effects of short-term treatment with arip-
iprazole has uncovered decreased levels of 5-HT
2A
 receptors 
in the PFC of young male rats,45 further investigations into 
the immediate and long-term effects of short- and long-term 
treatments will shed further light and allow further compari-
sons to be drawn to the current investigation findings.
In addition to the 5-HT
2A
 receptor changes, alterations to 
the 5-HT
2C
 receptor were found in the PFC and hippocampus 
of males only in the present study. Contrasting results were 
revealed between the aforementioned regions, with decreases 
in 5-HT
2C
 receptor levels uncovered in the PFC of adult male 
rodents following juvenile treatment with aripiprazole and 
olanzapine, while increases were found in the hippocampus 
of aripiprazole- and risperidone-treated groups in comparison 
to control.
Previous investigations into the immediate effects of 
APD treatment on 5-HT
2C
 receptor density levels have 
found differing results to that observed by the current study, 
where long-lasting effects were revealed. First, contrary to 
our study, alterations to 5-HT
2C
 receptors have been found 
across both male and female rodents in studies of varying 
treatment durations, utilizing both young and adult models, 
and through multiple brain regions. In addition, while olan-
zapine treatment has been found to decrease 5-HT
2C
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the PFC of studies, investigations into the immediate effects 
of short- and long-term APD treatment on 5-HT
2C
 receptors 
in the hippocampus of young and adult rodents have found 
treatment with olanzapine resulted in either a decrease or 
no change in the density of receptors.45,67,70,71 In particular, 
while short-term olanzapine treatment of both young male 
and female rodents resulted in immediate decreases across 
cortical and striatal brain regions,45 variations in results have 
been found in the immediate effects of adult olanzapine 
treatment models over both short-term70,71 and long-term 
periods,67 with either decreases or no change in receptor 
densities found in investigated brain regions including PFC, 
CPu, NAc, and hippocampus. Investigations into the effects 
of aripiprazole and risperidone on 5-HT2C receptor have 
been concentrated on the immediate effects of short-term 
treatment periods, with no alterations to any brain regions 
found following short-term aripiprazole treatment across both 
male and female young animals45 or short-term risperidone 
treatment in adult male rodents.70
Minimal changes in adult 5-HT
1A
 receptors were uncov-
ered following juvenile APD treatment in the present study. 
Decreases in 5-HT
1A
 receptor density levels in the adult brain 
were uncovered in the NAc following juvenile risperidone 
APD treatment in the male cohort, and in the NAc of female 
rodents treated with aripiprazole in comparison to the 
control. Previous investigations once again centered upon 
uncovering the immediate effect of treatment on 5-HT
1A
 
receptor density levels, with the majority of studies reveal-
ing no changes in receptor levels following APD treatment 
with aripiprazole, olanzapine, or risperidone in investigated 
regions. Some short-term studies did however reveal that 
acute and short-term treatment in both young and adult rats 
increased 5-HT
1A
 receptor density levels.46,70 Specifically, 
while increases in 5-HT
1A
 receptor density levels have been 
found previously across both the PFC and hippocampus of 
both young and adult male rodents following short-term treat-
ment with risperidone and olanzapine,46,70 acute treatment of 
female rats with aripiprazole has also uncovered increases in 
5-HT
1A
 levels in the hippocampus. No alterations, however, 
were found following acute and long-term olanzapine or 
haloperidol treatments and across cortical and hypothalamic 
brain regions.65
The minimal observed alterations to the 5-HT
1A
 receptor 




 may be due to a number 
of factors. First, of the three APDs investigated in the current 
study, only aripiprazole has been found to have a significant 
affinity for the 5-HT
1A
 receptor,65,72 while the similar antago-





 receptors may be resulting in the 
comparable decreases in adult brain receptor density levels 
between the two receptor subtypes.22 The 5-HT
1A
 is known to 
be located both pre- and postsynaptically and have autorecep-
tor functions.38,73,74 Investigations have found that the 5-HT
1A
 
receptor located presynaptically in the dorsal raphe nucleus, 
performing regulatory functions for the 5-HT NT, and also 
located postsynaptically in limbic structures including the 
hippocampus, performing traditional postsynaptic receptor 
functions.38,73,74





receptors, along with the presynaptic 5-HT
1A
 receptor, has 
the potential to result in a downregulation in number and 
sensitivity and subsequently a long-term deficiency in 5-HT 
NT signaling.38,75,76 With the 5-HT
2A
 receptor in particular 
well known to play critical roles in both APD treatment 
efficacy19–22 and the regulation and functioning of the 5-HT 
NT system,36–38,77,78 and with previous investigations dem-
onstrating a correlative functions of the 5-HT NT in the 
pathophysiology of multiple mental illnesses,16,22,29,38,79,80 any 
disturbances to the regulation of the 5-HT NT system, such 
as through early APD treatment targeting 5-HT receptors, 
have the potential to alter 5-HT transmission and, thus, elicit 
related changes to multiple facets of mental illness over long 
term. Furthermore, the subsequent deficiency in projections 
of the 5-HT NT has been found to result in the disinhibi-
tion and therefore enhancement of the DA signal36–38 and 
correlated to changes in behaviors, as demonstrated in our 
previous investigations.35,39 Changes in behaviors including 
enhanced locomotor activity36,37 and anxiolytic and decreased 
depressive-like behaviors8,36,75,81–84 have previously been 
uncovered and correlated to the repeated antagonism of the 
5-HT
2
 receptor, potentially the negatively correlated altera-
tions to the DA signal.
APDs such as aripiprazole have also been found to elicit 
partial agonist effects on presynaptic 5-HT
1A
 receptors in 
the dorsal raphe nuclei of previously investigated brains,76,85 
Investigations into the effects of APD treatment on 5-HT 
receptors in the dorsal raphe nuclei, however, will need to 
be the focus of future studies, as the focus of the current 
investigations only shifted to the 5-HT NT system following 
previous results, and thus, no relevant tissue is available for 
analysis.
With previous investigations into the effects of APD 
treatment on 5-HT receptors centered upon revealing any 
immediate changes in receptor density levels, and the current 
study looking into long-lasting effects, the contrasting results 
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product of a myriad of influencing factors. Factors including 
the treatment duration of the study, differences in age of the 
animals treated, and duration of time between the cessation of 
APD treatment and detection of 5-HT receptors have previ-
ously been highlighted as having the potential to influence 
the observed results, with the current study specifically inves-
tigating the long-term effects of juvenile APD treatment on 
5-HT receptors in the adult brain. There is the potential that 
the alterations to measured variables uncovered in the pres-
ent study may have occurred following the cessation of APD 
treatment and during the drug withdrawal period. During such 
time, the antagonistic action of APDs on 5-HT receptors in 
an adult brain may result in a short-term over-compensatory 
increase in receptor numbers (as observed in previous investi-
gations65), followed by a regulation of density over long term. 
Drug treatment during the critical neurodevelopmental time 
period may subsequently result in a long-term decrease in 
morphology and/or density over the large time duration, in a 
process previously labeled as neuronal imprinting.25 Previous 
studies have demonstrated similar age-dependent effects of 
drug treatment, with psychotropic drugs such as fluoxetine 
(a selective serotonin re-uptake inhibitor [SSRI]) previously 
proven to elicit different effects on a juvenile compared to 
an adult, mature brain.25,34,86,87
Chronologically, and as outlined briefly earlier, 5-HT is 
also known to play a significant role first as a trophic factor 
in overall brain development and then undergo significant 
neurodevelopmental phases itself as the NT system develops 
from birth through to adulthood.8,31 Specifically, the 5-HT 
ligand, along with the 5-HT
1A
 receptor, has been found to 
play key roles in overall axonal growth and synapse forma-
tion throughout the brain.88 Alterations to baseline levels of 
5-HT during these early critical phases of neurodevelopment, 
through either intrinsic or extrinsic factors (eg, early APD 
treatment), have been found to alter the developmental trajec-
tory of the adult brain and subsequently impact the adult brain 
functioning.8,26,30,32,88 Therefore, there is the potential that the 
juvenile APD treatment utilized in the present study, with 
a high affinity and potent actions on the 5-HT NT system, 
has impacted not only the observed long-lasting changes in 
5-HT receptors but also widespread long-lasting alterations 
to overall axonal growth, neurite, and dendrite formations.
Additionally, and as indicated previously, gender-specific 
alterations to adult 5-HT receptor density levels were also 
observed following juvenile APD treatment in the present 





 receptors were uncovered in the PFC 
and hippocampus of males, while minimal alterations were 
observed in the female cohort across all investigated 5-HT 
receptor subtypes and across all four brain regions and 
APD treatment groups. Potential influencing factors on the 
observed gender differences in results have been outlined 
extensively in previous publications.35,39 Specifically, the 
well-known differences in the development and expression 
of 5-HT receptors between genders89 and with the influence 
of the sex hormones testosterone and estrogen26,82,89–91 have 
the potential to play a role in the observed gender differ-
ences. Previously demonstrated gender variations to 5-HT-
mediated functions have an obvious potential to influence 
the observed results,89,92 with the sex hormones testosterone 
and estrogen found to play a critical role.89,91,93–96 Changes in 
the levels of the sex hormone estrogen have been found to 
influence the levels of 5-HT ligand in brain regions including 
the cortex and raphe nucleus94–96 and, furthermore, alter the 




 receptors in brain regions 
including the cortex, raphe nucleus, and hippocampus.89 
Additionally, estrogen has previously been found to play 
a neuro-protective effect on 5-HT NT system, with studies 
uncovering its ability to inhibit behavioral changes in infor-
mation processing mediated by both the 5-HT
1A
 and DA D
2
 
receptors, an attribute that found deficient in people suffering 
from mental illness.90
Conclusion
The current study has uncovered the potential for treatment 
with the APDs aripiprazole, olanzapine, and risperidone 
during the critical neurodevelopmental period to cause long-
lasting alterations to the density of 5-HT receptors in the 





 receptors in cortical and hippocampal brain 
regions were observed in the male cohort across aripiprazole, 
olanzapine, and risperidone APD treatment groups in com-
parison to controls. These observed changes are in addition 
to the alterations to various behavioral attributes (including 
anxiety and depressive-like behaviors) and the dopamine 
NT system (including receptors, transporters, and synthesis 
markers) previously reported with the same treatment model 
in our laboratory.35,39 Although the observed alterations to the 
5-HT NT system in the investigated regions provide some 
evidence of the potential for early APD treatment to elicit 
long-term alterations to a NT system functioning, further 
investigations have the potential to uncover both the scope 
of changes elicited on the 5-HT NT system and potential 
alterations to other NT groups. Other NT systems including 
the adrenergic and muscarinic NT systems are also known 
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APDs and interplay with other NT systems,37,97–99 and thus, 
antagonist actions during the critical neurodevelopmental 
time period have the potential to elicit long-lasting changes 
that may be exhibited clinically. Furthermore, investigations 
into the effects of juvenile APD in a disease animal model 
would also provide invaluable insight into the potential long-
lasting effects of treatment during such a critical neurodevel-
opmental time period. The alterations observed in the present 
study provide some of the first evidence of the potential of 
juvenile APD treatment with aripiprazole, olanzapine, and 
risperidone to elicit long-term alterations to the 5-HT NT 
system in the adult brain. With all three APDs approved for 
use in adolescents with various medical conditions and also 
known to be prescribed off-label, the potential long-term 
effects of early use should be highlighted before they are 
prescribed clinically, especially in the male cohort where 
the vast majority of alterations have been found.
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